HLB Co.,LTD.
Multi-business group in healthcare, biotech, and shipbuilding, developing the oral anticancer drug rivoceranib and the cholangiocarcinoma therapy RLY-4008.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 1985 and listed on KOSDAQ in 1996, the company operates three business segments: healthcare, biotech, and shipbuilding. In biotech, it holds the oral angiogenesis-inhibiting TKI rivoceranib and the cholangiocarcinoma drug RLY-4008 (lirafugratinib) licensed from Relay Therapeutics. Rivoceranib's NDA was submitted to the US FDA in May 2023, and the company acquired its global ex-China patent rights from Advenchen Laboratories for USD 22M and its China patent rights from SFFT Developing for USD 20M, both in September 2020.
Products & technology
- body care deviceMedia-commerce consumer product
- plant-based melatonin ODFMedia-commerce consumer product
Regulatory approvals
openFDA1 US FDA 510(k) · 2025
- FDASterilized Eol Auto Lancet; Sterilized Eol Lancet Plus2025-01-13
R&D and key agreements
Source: DART corporate disclosure리보세라닙(Rivoceranib) · 간세포암 1차 치료(캄렐리주맙 병용) · 임상3상 결과 발표, FDA NDA 제출 · Oral TKI targeting angiogenesis; Phase 3 results for 1st-line hepatocellular carcinoma (with camrelizumab) announced Sep 2022; FDA NDA submitted May 2023; final results presented at ASCO Jun 2024
RLY-4008(리라푸그라티닉) · 담관암 · 라이선스 도입, 혁신신약 지정 · Global exclusive license-in from Relay Therapeutics in Dec 2024; granted Breakthrough Therapy designation
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition